The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, vol.12, pp.252-264, 2012. ,
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med, vol.373, pp.23-34, 2015. ,
Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med, vol.372, pp.2521-2532, 2015. ,
Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N. Engl. J. Med, vol.377, pp.1345-1356, 2017. ,
Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase i doseescalation study, J. Clin. Oncol, vol.36, pp.391-398, 2018. ,
Evolving synergistic combinations of targeted immunotherapies to combat cancer, Nat. Rev. Cancer, vol.15, pp.457-472, 2015. ,
Sphingolipid metabolism in cancer signalling and therapy, Nat. Rev. Cancer, vol.18, pp.33-50, 2018. ,
Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells, Oncogene, vol.33, pp.3364-3373, 2014. ,
Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma, Oncotarget, vol.7, pp.71873-71886, 2016. ,
The role of sphingosine 1-phosphate in inflammation and cancer, Adv. Biol. Regul, vol.54, pp.121-129, 2014. ,
Sphingosine 1-phosphate and cancer, Nat. Rev. Cancer, vol.10, pp.489-503, 2010. ,
Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond, Immunology, vol.142, pp.347-353, 2014. ,
The outs and the ins of sphingosine-1-phosphate in immunity, Nat. Rev. Immunol, vol.11, pp.403-415, 2011. ,
The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, vol.12, pp.298-306, 2012. ,
The immune contexture in cancer prognosis and treatment, Nat. Rev. Clin. Oncol, vol.14, pp.717-734, 2017. ,
Regulatory T cells in cancer immunotherapy, Curr. Opin. Immunol, vol.27, pp.1-7, 2014. ,
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes, Oncoimmunology, vol.3, p.29244, 2014. ,
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations, Pigment Cell Melanoma Res, vol.29, pp.590-597, 2016. ,
Broadspectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation, Cell, vol.156, pp.986-1001, 2014. ,
Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells, Cancer Immunol. Res, vol.4, pp.845-857, 2016. ,
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, vol.114, pp.1537-1544, 2009. ,
PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors, J. Clin. Invest, vol.124, pp.2246-2259, 2014. ,
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat. Med, vol.10, pp.942-949, 2004. ,
CCR4 as a novel molecular target for immunotherapy of cancer, Cancer Sci, vol.97, pp.1139-1146, 2006. ,
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function, Cancer Cell, vol.26, pp.923-937, 2014. ,
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions, Nat. Immunol, vol.15, pp.431-438, 2014. ,
Eicosanoids and cancer, Nat. Rev. Cancer, vol.10, pp.181-193, 2010. ,
Membrane prostaglandin E synthase-1: a novel therapeutic target, Pharm. Rev, vol.59, pp.207-224, 2007. ,
, Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell, vol.161, pp.1681-1696, 2015.
Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue, J. Histochem. Cytochem, vol.53, pp.1159-1166, 2005. ,
Sphingosine kinase 1 is up-regulated in colon carcinogenesis, FASEB J, vol.20, pp.386-388, 2006. ,
Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients, Clin. Cancer Res, vol.15, pp.1393-1399, 2009. ,
Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population, Clin. Transl. Gastroenterol, vol.5, p.51, 2014. ,
Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer, Int J. Cancer, vol.132, pp.605-616, 2013. ,
Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptornegative breast cancer, Br. J. Cancer, vol.106, pp.1453-1459, 2012. ,
Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines, J. Neuropathol. Exp. Neurol, vol.64, pp.695-705, 2005. ,
Sphingosine kinase 1 and cancer: a systematic review and meta-analysis, PLoS ONE, vol.9, p.90362, 2014. ,
Extracellular and intracellular actions of sphingosine-1-phosphate, Adv. Exp. Med. Biol, vol.688, pp.141-155, 2010. ,
Sphingosine-1-phosphate signaling and its role in disease, Trends Cell Biol, vol.22, pp.50-60, 2012. ,
Regulation of limb development by the sphingosine 1-phosphate receptor S1p1/EDG-1 occurs via the hypoxia/VEGF axis, Dev. Biol, vol.268, pp.441-447, 2004. ,
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages, Cancer Cell, vol.9, pp.225-238, 2006. ,
S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3, Cell Rep, vol.6, pp.992-999, 2014. ,
Genome-wide in vivo screen identifies novel host regulators of metastatic colonization, Nature, vol.541, pp.233-236, 2017. ,
Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network, FASEB J, vol.27, pp.1001-1011, 2013. ,
Effect of sphingosine kinase 1 inhibition on blood pressure, FASEB J, vol.27, pp.656-664, 2013. ,
Cyclooxygenase-dependent tumor growth through evasion of immunity, Cell, vol.162, pp.1257-1270, 2015. ,
PGI2 as a regulator of CD4+ subset differentiation and function, Prostaglandins Other Lipid Mediat, vol.96, pp.21-26, 2011. ,
PGD synthase and PGD2 in immune resposne, Mediators Inflamm, p.503128, 2012. ,
Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune response, Nat. Commun, vol.7, p.13464, 2016. ,
Novel genes associated with malignant melanoma but not benign melanocytic lesions, Clin. Cancer Res, vol.11, pp.7234-7242, 2005. ,
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases, Mol. Cancer Res, vol.6, pp.760-769, 2008. ,
, Sphingolipids in macroautophagy. Methods Mol. Biol, vol.445, pp.159-173, 2008.
Extracellular IL-33 cytokine, but not endogenous nuclear IL-33, regulates protein expression in endothelial cells, Sci. Rep, vol.6, p.34255, 2016. ,
, the Transcan-2 Research Program, which is a transnational R&D program jointly funded by national funding organizations within the framework of the ERA-NET Transcan-2
) for the kind gift of NSG mice and Dr. C. Lachaud (CRCM; Marseille, France) for the generation of stable cell line using the CRIPSR/Cas9 technology. We acknowledge the assistance of Drs, LNCC and Fondation pour la Recherche Médicale (FRM). The IBiSA Toulouse Proteomics facility is supported by the following institutions: Région Midi-Pyrénées, Fonds Européens de Développement Régional, Toulouse Métropole, and the French Ministry of Research with the 'Investissement d'Avenir Infrastructures Nationales en Biologie et Santé program' (Proteomics French Infrastructure project ,